Chinese acquisition of US chemical tech company falls apart amid CFIUS review

A Chinese pharmaceutical company has abandoned its acquisition of a US-based chemical technology business after failing to address concerns raised by the Committee on Foreign Investment in the United States.

Unlock unlimited access to all Global Competition Review content